Browse articles from EyeWorld.org related to DMEK. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
A pair of recent studies from the Diabetes Endothelial Keratoplasty Study Group published in JAMA Ophthalmology found that diabetes status did not affect success of DMEK outcomes overall, nor did it result in greater endothelial cell loss when compared to tissue from a donor without diabetes.
➤ Complete response letter issued for low-dose atropine drop ➤ Extension study shows reduced GA growth with intravitreal treatment ➤ Durable, 3-year vision improvements seen with optogenetic therapy ➤ Preclinical data supports long-acting nature of investigational anti-VEGF for wet AMD ➤ Company news ➤ ASCRS news and events
➤ FDA approves epithelium-on crosslinking treatment ➤ 12-month results from Phase 1/2 trial evaluating regenerative cell therapy for corneal endothelial disease ➤ Phase 3 data supports nonsteroidal treatment for uveitic macular edema ➤ FDA approves IDE for glaucoma device ➤ Company news ➤ ASCRS news and events
➤ Accommodating lens implanted in first patient ➤ First patient dosed in Phase 2 trial investigating treatment for normal tension glaucoma ➤ Primary endpoint met in Phase 3 trial for glaucoma drop ➤ CE mark approvals ➤ Regenerative Medicine Advanced Therapy designation granted to investigational gene therapy for Stargardt disease ➤ ASCRS news and events
Three physicians discussed the recent uptick in primary graft failures, the data, and the potential culprit.
The learning curve for DMEK is steep, but most training opportunities are reserved for those in a cornea fellowship. Objective data on the efficiency of wet labs, which don’t pose a risk to patients, don’t waste valuable tissue, and are available to those at earlier skill levels, was recently published.
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop ➤ Phase 2b results for drug-eluting contact lens for glaucoma ➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis ➤ Higher dose, extended wet AMD treatment non-inferior to standard of care ➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Update on safety review of geographic atrophy drug ➤ IND application accepted by FDA for wet AMD gene therapy ➤ Phase 2 trial planned for investigational neuropathic corneal pain treatment ➤ Interim Phase 2 data for sustained wet AMD treatment ➤ ASCRS news and events
“Best practices are the summation of the technical aspects of medicine. They are, in effect, the perfection of the form of medicine,” said Julie Schallhorn, MD. She shared this and other thoughts on best practices and gave a preview of the articles in the Cornea section of the issue.